Earlier this morning, AstraZeneca PLC (LON:AZN) announced the approval of a new easy-to-use formulation to treat patients with type-2 diabetes in Europe.
Bydureon BCise is the new formulation of once-weekly Bydureon. It is an improved single-dose, pre-filled pen device that can be used alongside other glucose-lowering drugs. Bydureon BCise will improve glycaemic control in adults with type-2 diabetes.
The approval of the European Commission follows two clinical trials that produced data to support the use of Bydureon BCise, DURATION-NEO-1 and NEO-2.
AstraZeneca is an international biopharmaceutical company operating in over 100 countries and treating millions of patients worldwide. The company drives the discovery and development of prescription medicine primarily to treat Oncology, Cardiovascular, Renal & Metabolism and Respiratory diseases.
AstraZeneca’s Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development, Elisabeth Björk, has commented:
“Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.”
Whilst the European Commission has only just approved Bydureon BCise, the US Food and Drug Administration approved its use almost a year ago.
